“Use of these products according to labeled instructions with an affected dosing cup is unlikely to result in serious side effects, and no reports related to overdose have been received to date,” according to a news release from Perrigo. “Consumers should be aware that an overdose of Guaifenesin DM may cause hyper excitability, rapid eye movements, changes in muscle reflexes, ataxia, dystonia, hallucinations, stupor and coma. Other effects have included nausea, vomiting, tachycardia, irregular heartbeat, seizures, respiratory depression and death.”
Perrigo has included the labels and batch numbers corresponding with potentially defective dosing cups in the release.
More articles on quality:
7 questions with a pediatrician in the thick of Flint’s lead poisoning crisis
TB outbreak leaves 3 dead in Alabama: 3 things to know
CDC: Patients test positive for hepatitis C in investigation at 2 Utah hospitals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.